Search results
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
Zacks via Yahoo Finance· 2 years agoSanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and...
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
Zacks via Yahoo Finance· 1 year agoAmicus FOLD announced that the European Commission approved cipaglucosidase alfa, commercialized...
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
Zacks via Yahoo Finance· 8 months agoAmicus Therapeutics FOLD announced that the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda...
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
Zacks via Yahoo Finance· 6 months agoSanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready...
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Zacks via Yahoo Finance· 3 months agoAmicus Therapeutics, Inc. FOLD reported fourth-quarter 2023 adjusted earnings of 1 cent per share...
Amicus' muscle disorder therapy gets US FDA nod but restricted label drags shares
Reuters via Yahoo News· 8 months ago(Reuters) -Amicus Therapeutics' treatment for a rare muscle disorder called Pompe disease was...
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
Zacks via Yahoo Finance· 5 months agoSales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of...
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Benzinga via Yahoo Finance· 2 years agoThe FDA has placed a clinical hold on Astellas Pharma Inc's (OTC: ALPMY) FORTIS Phase 1/2 trial...
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – July 1, 2022 – Zacks.com announces the list of stocks featured...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript March 1, 2023 Operator:...